Which has higher earnings & valuation, BCT or MDNA?

BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BriaCell Therapeutics N/A N/A N/A -C$0.38 N/A Medicenna Therapeutics N/A N/A -C$25.98M -C$0.22 N/A

Which has higher valuation & earnings, MDNA or HBP?

Helix BioPharma is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medicenna Therapeutics N/A N/A -C$25.98M -C$0.22 N/A Helix BioPharma N/A N/A -C$50.55M -C$0.04 N/A

Which has stronger earnings & valuation, SCYB or MDNA?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scythian Biosciences N/A N/A N/A N/A N/A Medicenna Therapeutics N/A N/A -C$25.98M -C$0.22 N/A

Which has higher valuation & earnings, MDNA or COM?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Medicenna Therapeutics N/A N/A -C$25.98M -C$0.22 N/A 138267 (COM.TO) N/A N/A N/A N/A N/A

Medicenna Therapeutics (MDNA) Competitors

C$0.46 -0.01 (-2.13%)

As of 04:00 PM Eastern

Compare

MDNA vs. BCT, HBP, SCYB, COM, and NVH

Should you buy Medicenna Therapeutics stock or one of its competitors? Medicenna Therapeutics's main competitors and comparable companies include BriaCell Therapeutics (BCT), Helix BioPharma (HBP), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), and Novoheart (NVH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Medicenna Therapeutics compare to BriaCell Therapeutics?

BriaCell Therapeutics (CVE:BCT) and Medicenna Therapeutics (TSE:MDNA) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership.

BriaCell Therapeutics has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. BriaCell Therapeutics' return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BriaCell Therapeutics	N/A	N/A	N/A
Medicenna Therapeutics	-533,640.00%	-360.29%	-32.80%

BriaCell Therapeutics is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BriaCell Therapeutics	N/A	N/A	N/A	-C$0.38	N/A
Medicenna Therapeutics	N/A	N/A	-C$25.98M	-C$0.22	N/A

In the previous week, BriaCell Therapeutics' average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.

Company	Overall Sentiment
BriaCell Therapeutics	Neutral
Medicenna Therapeutics	Neutral

0.4% of Medicenna Therapeutics shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Medicenna Therapeutics beats BriaCell Therapeutics on 4 of the 7 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Helix BioPharma?

Medicenna Therapeutics (TSE:MDNA) and Helix BioPharma (TSE:HBP) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, risk, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and dividends.

0.4% of Medicenna Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Helix BioPharma shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by insiders. Comparatively, 2.2% of Helix BioPharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Helix BioPharma had 1 more articles in the media than Medicenna Therapeutics. MarketBeat recorded 1 mentions for Helix BioPharma and 0 mentions for Medicenna Therapeutics. Helix BioPharma's average media sentiment score of 0.75 beat Medicenna Therapeutics' score of 0.00 indicating that Helix BioPharma is being referred to more favorably in the news media.

Company	Overall Sentiment
Medicenna Therapeutics	Neutral
Helix BioPharma	Positive

Medicenna Therapeutics has a beta of 2.96881, meaning that its share price is 197% more volatile than the broader market. Comparatively, Helix BioPharma has a beta of 0.433836, meaning that its share price is 57% less volatile than the broader market.

Helix BioPharma is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicenna Therapeutics	N/A	N/A	-C$25.98M	-C$0.22	N/A
Helix BioPharma	N/A	N/A	-C$50.55M	-C$0.04	N/A

Helix BioPharma has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Helix BioPharma's return on equity of -21.54% beat Medicenna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicenna Therapeutics	-533,640.00%	-360.29%	-32.80%
Helix BioPharma	N/A	-21.54%	-279.98%

Summary

Medicenna Therapeutics beats Helix BioPharma on 6 of the 11 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Scythian Biosciences?

Scythian Biosciences (CVE:SCYB) and Medicenna Therapeutics (TSE:MDNA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, valuation, analyst recommendations, media sentiment and dividends.

0.4% of Medicenna Therapeutics shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Scythian Biosciences has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Scythian Biosciences' return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scythian Biosciences	N/A	N/A	N/A
Medicenna Therapeutics	-533,640.00%	-360.29%	-32.80%

In the previous week, Scythian Biosciences' average media sentiment score of 0.00 equaled Medicenna Therapeutics'average media sentiment score.

Company	Overall Sentiment
Scythian Biosciences	Neutral
Medicenna Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scythian Biosciences	N/A	N/A	N/A	N/A	N/A
Medicenna Therapeutics	N/A	N/A	-C$25.98M	-C$0.22	N/A

Summary

Scythian Biosciences beats Medicenna Therapeutics on 3 of the 5 factors compared between the two stocks.

How does Medicenna Therapeutics compare to 138267 (COM.TO)?

Medicenna Therapeutics (TSE:MDNA) and 138267 (COM.TO) (TSE:COM) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

In the previous week, Medicenna Therapeutics' average media sentiment score of 0.00 equaled 138267 (COM.TO)'saverage media sentiment score.

Company	Overall Sentiment
Medicenna Therapeutics	Neutral
138267 (COM.TO)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicenna Therapeutics	N/A	N/A	-C$25.98M	-C$0.22	N/A
138267 (COM.TO)	N/A	N/A	N/A	N/A	N/A

0.4% of Medicenna Therapeutics shares are owned by institutional investors. 22.6% of Medicenna Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

138267 (COM.TO) has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. 138267 (COM.TO)'s return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicenna Therapeutics	-533,640.00%	-360.29%	-32.80%
138267 (COM.TO)	N/A	N/A	N/A

Summary

138267 (COM.TO) beats Medicenna Therapeutics on 3 of the 5 factors compared between the two stocks.

How does Medicenna Therapeutics compare to Novoheart?

Medicenna Therapeutics (TSE:MDNA) and Novoheart (CVE:NVH) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Novoheart has higher revenue and earnings than Medicenna Therapeutics. Novoheart is trading at a lower price-to-earnings ratio than Medicenna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medicenna Therapeutics	N/A	N/A	-C$25.98M	-C$0.22	N/A
Novoheart	C$423.50K	236.08	-C$7.17M	-C$0.04	N/A

0.4% of Medicenna Therapeutics shares are held by institutional investors. 22.6% of Medicenna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Novoheart has a net margin of 0.00% compared to Medicenna Therapeutics' net margin of -533,640.00%. Novoheart's return on equity of 0.00% beat Medicenna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Medicenna Therapeutics	-533,640.00%	-360.29%	-32.80%
Novoheart	N/A	N/A	N/A

In the previous week, Medicenna Therapeutics' average media sentiment score of 0.00 equaled Novoheart'saverage media sentiment score.

Company	Overall Sentiment
Medicenna Therapeutics	Neutral
Novoheart	Neutral

Summary

Novoheart beats Medicenna Therapeutics on 6 of the 9 factors compared between the two stocks.

Get Medicenna Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MDNA vs. The Competition

Export

Metric	Medicenna Therapeutics	Biotechnology Industry	Healthcare Sector	TSE Exchange
Market Cap	C$42.46M	C$3.99B	C$7.20B	C$12.38B
Dividend Yield	N/A	3.61%	2.53%	6.24%
P/E Ratio	-2.09	12.25	272.63	39.34
Price / Sales	N/A	1,326.16	616.73	9.80
Price / Cash	1.15	105.29	76.98	82.29
Price / Book	23.82	16.19	12.85	4.68
Net Income	-C$25.98M	-C$22.72M	C$3.47B	C$299.09M
7 Day Performance	-2.13%	-1.18%	-0.22%	-1.51%
1 Month Performance	27.78%	12.75%	8.04%	4.09%
1 Year Performance	-56.60%	53.86%	25.08%	27.89%

Medicenna Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MDNA Medicenna Therapeutics	N/A	C$0.46 -2.1%	N/A	-56.9%	C$42.46M	N/A	N/A	20	Gap Down
BCT BriaCell Therapeutics	N/A	C$10.60 -3.8%	N/A	+0.0%	C$168.68M	N/A	N/A	5
HBP Helix BioPharma	N/A	C$1.90 flat	N/A	+31.6%	C$145.12M	N/A	N/A	9	News Coverage Gap Up
SCYB Scythian Biosciences	N/A	C$3.49 -5.9%	N/A	+0.0%	C$102.38M	N/A	N/A	N/A	High Trading Volume
COM 138267 (COM.TO)	N/A	N/A	N/A	N/A	C$102.19M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (TSE:MDNA) was last updated on 9/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Medicenna Therapeutics (MDNA) Competitors

MDNA vs. BCT, HBP, SCYB, COM, and NVH

How does Medicenna Therapeutics compare to BriaCell Therapeutics?

Summary

How does Medicenna Therapeutics compare to Helix BioPharma?

Summary

How does Medicenna Therapeutics compare to Scythian Biosciences?

Summary

How does Medicenna Therapeutics compare to 138267 (COM.TO)?

Summary

How does Medicenna Therapeutics compare to Novoheart?

Summary

Media Sentiment Over Time

MDNA vs. The Competition

Medicenna Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Medicenna Therapeutics (MDNA) Competitors

MDNA vs. BCT, HBP, SCYB, COM, and NVH

How does Medicenna Therapeutics compare to BriaCell Therapeutics?

Is BCT or MDNA more profitable?

Which has higher earnings & valuation, BCT or MDNA?

Does the media prefer BCT or MDNA?

Do insiders & institutionals hold more shares of BCT or MDNA?

Summary

How does Medicenna Therapeutics compare to Helix BioPharma?

Do institutionals & insiders have more ownership in MDNA or HBP?

Does the media refer more to MDNA or HBP?

Which has more risk & volatility, MDNA or HBP?

Which has higher valuation & earnings, MDNA or HBP?

Is MDNA or HBP more profitable?

Summary

How does Medicenna Therapeutics compare to Scythian Biosciences?

Do insiders & institutionals have more ownership in SCYB or MDNA?

Is SCYB or MDNA more profitable?

Does the media prefer SCYB or MDNA?

Which has stronger earnings & valuation, SCYB or MDNA?

Summary

How does Medicenna Therapeutics compare to 138267 (COM.TO)?

Does the media favor MDNA or COM?

Which has higher valuation & earnings, MDNA or COM?

Do institutionals & insiders believe in MDNA or COM?

Is MDNA or COM more profitable?

Summary

How does Medicenna Therapeutics compare to Novoheart?

Which has better valuation & earnings, MDNA or NVH?

Do insiders and institutionals hold more shares of MDNA or NVH?

Is MDNA or NVH more profitable?

Does the media refer more to MDNA or NVH?

Summary

Media Sentiment Over Time

MDNA vs. The Competition

Medicenna Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools